NEW YORK (GenomeWeb News) – The Medical College of Wisconsin said on Wednesday that it has been awarded a four-year, $1.5 million grant from the National Heart, Lung, and Blood Institute to investigate genetic variants that may contribute to end-stage renal disease (ESRD).
Researchers from Weill Cornell Medical College and the Rogosin Institute have developed a next-generation sequencing approach for diagnosing autosomal dominant polycystic kidney disease, which they showed could equal or exceed the efficiency and accuracy of current Sanger sequenc
NEW YORK (GenomeWeb News) – A New England Journal of Medicinestudy suggests high-risk variants in the apolipoprotein L1 gene APOL1 can contribute to more rapid kidney disease progression in individuals of A
NEW YORK (GenomeWeb News) – The Carlos Slim Foundation has pledged $74 million to fund the second phase of a genomics-focused collaboration between the Broad Institute, Mexico's National Institute of Genomic Medicine, and the Carlos Slim Health Institute, Broad said today.
NEW YORK (GenomeWeb News) – Researchers at the Icahn School of Medicine at Mount Sinai will use a $3.7 million grant from the National Human Genome Research Institute to try to find out if the use of genomic information and electronic medical records can improve treatment of kidney disease patien
NEW YORK (GenomeWeb News) – The National Institute of Diabetes, Digestive, and Kidney Diseases has established a biosample and data repository using samples from many of the clinical studies and trials it has funded, and it now
NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) and MRM Proteomics announced today that they will partner on proteomic-based diagnostic tests for patients with chronic organ diseases.
NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure, or PROOF Centre, and IO Informatics today announced a deal to develop a web-based software application addressing chronic heart, lung, and kidney disease.
Belgian protein biomarker firm Pronota has raised €3.7 million ($4.9 million) a Series C financing round that it will use to complete protein biomarker validation studies for its pre-eclampsia, ovarian cancer, sepsis, and cardio-renal programs.